In patients with benign prostate hyperplasia who received tamsulosin 0.2 mg for more than 4 weeks, the improvement of the lower urinary tract symptom terazosin 5 mg administered for 12 weeks

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004566

Enrollment

Registered

2019-12-19

Start date

2019-12-23

Completion date

Unknown

Last updated

2020-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Terazosin 5mg QD in patients with prostatic hyperplasia who had taken Tamsulosin 0.2mg for more than 4 weeks and had no significant improvement in lower urinary tract symptoms

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Male over 40 years 2) Patients diagnosed with benign prostatic hyperplasia 3) Patients have an IPSS score of at least 8 4) Patients who have been prescribed Tamsulosin 0.2mg for more than 4 weeks but have no significant improvement in IPSS score or maximum urinary velocity (Qmax) 5) Patients who voluntarily decided to participate in this study and agreed in writing to the subject consent form

Exclusion criteria

Exclusion criteria: 1) Patients with hypersensitivity to a-blocker family drugs. 2) Patients who are taking cholinergic drugs, diuretics, or ß3-antagonists. 3) Patients with urination disorders due to obvious causes other than benign prostatic hyperplasia. 4) Patients with neurogenic bladder disorders. 5) Patients with urinary tract infections (midstream urine culture> 100,000 colonies/mL) 6) Patients with clinically significant circulatory disorders (myocardial infarction, heart failure, angina pectoris, cardiac arrhythmias, pacemaker use, orthostatic hypotension, uncontrolled hypotension) 7) Participants in other interventions within 6 months of screening 8) Patients who are inappropriate to participate in research as judged by other research managers or researchers

Design outcomes

Primary

Measure	Time frame
International Prostate Symptom Score(IPSS) Improvement	—

Secondary

Measure	Time frame
Assessment of improvement in maximum urine velocity(Qmax);IPSS-QoL Improvement Assessment	—

Countries

Korea, Republic of

Contacts

Public ContactHyung Ji Kim

Dankook Univeristy Hospital

Outcome results